Oct
2026
Fiera Milano, Italy
Visit us
stand 7D131, Integrated Pharma
Zone

Medi-Radiopharma

Exhibitor at CPHI Milan 2026
About Us

Medi-Radiopharma is a trusted CDMO partner with 30 years of expertise in nuclear medicine. We deliver end-to-end GMP solutions for liquid and lyophilized sterile injectables, from development to commercial-scale manufacturing. Our services include API synthesis, QbD-driven formulation, tech transfer, and packaging—supported by state-of-the-art facilities and a passionate team. Flexible, compliant, and innovative, we help you accelerate projects and bring life-saving drugs to market

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Hungary
  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
CMO/CDMO
Pharmaceutical company
Primary activities
Analytical Services
Biopharmaceutical
Contract Manufacturer
Laboratory Services
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 7D131, Integrated Pharma

Products Featured at CPHI Milan 2026

  • Advanced Aseptic & Lyo Technologies, GMP Manufacturing & Packaging

    Product Advanced Aseptic & Lyo Technologies, GMP Manufacturing & Packaging

    As a GMP-certified CDMO, we offer end-to-end solutions tailored to the needs of the pharmaceutical and nuclear medicine industries. Our expertise extends the entire development and production lifecycle, with highest quality and compliance standards.

    - Liquid & Lyophilized Products – Scalable...

Medi-Radiopharma Resources (1)

  • MRP's New fill-finish facility in Budapest, Hungary

    Video MRP's New fill-finish facility in Budapest, Hungary

    In 2025, Medi-Radiopharma expands its capabilities with a state-of-the-art 6,000 m² GMP facility, boosting our annual capacity by 1.2 million vials. The site features advanced aseptic fill-finish lines, lyophilization technologies, in-house microbiology labs, and integrated packaging solutions. This investment strengthens our position as a trusted CDMO partner, delivering scalable, high-quality sterile manufacturing for innovative therapies worldwide.
    2025-09-03